Dissociation of thymidylate biosynthesis from DNA biosynthesis by 5-fluoro-2'-deoxyuridine and 5,8-dideazaisofolic acid.
The effects of 5-fluoro-2'-deoxyuridine (FdUrd) and 5,8-dideazaisofolic acid on the coordination of thymidylate synthase activity and DNA synthesis were examined in human CCRF-CEM leukemic cells following a continuous exposure to these agents. In logarithmically growing control tumor cells, the rate of in situ thymidylate synthase activity equaled the rate of DNA synthesis. However, in tumor cells incubated with growth-inhibitory concentrations of either FdUrd or 5,8-dideazaisofolic acid for 48 h, the rate of thymidylate synthase activity was between 15- and 17-fold greater than the rate of DNA synthesis. The loss in tumor cell viability of FdUrd-treated cells was temporally related to this prolonged dissociation of thymidylate biosynthesis from DNA biosynthesis. The dissociation of thymidylate from DNA biosynthesis in cells incubated with FdUrd was not closely related to thymidylate depletion. The intracellular concentrations and activities of thymidylate synthase were comparable in tumor cells incubated for 24 or 48 h with either a growth-inhibitory or non-growth-inhibitory concentration of FdUrd, indicating no direct relationship among these parameters. Indirect thymidylate depletion induced by the combination of 2,4-diamino-5-(3',4'-dichlorophenyl)-6-methylpyrimidine, hypoxanthine, and glycine inhibited in situ thymidylate synthase activity and DNA synthesis to an equal extent. In addition, the intracellular concentrations of all four deoxyribonucleoside 5'-triphosphates in tumor cells incubated with FdUrd for 48 h were between 1.3- and 3.1-fold greater than their respective concentrations in control cells, reflecting their decreased utilization in DNA synthesis in FdUrd-treated cells. These data indicated that inhibition of CCRF-CEM cell growth and DNA synthesis following a continuous exposure to cytostatic concentrations of either FdUrd or 5,8-dideazaisofolic acid resulted primarily from interference with thymidylate incorporation into DNA, and not simple blockade of thymidylate synthase.
D004247:DNA / Q000096:biosynthesis*; D004257:DNA Polymerase II / Q000032:analysis; D003848:Deoxyguanine Nucleotides / Q000032:analysis; D004305:Dose-Response Relationship, Drug; D005467:Floxuridine / Q000494:pharmacology*; D005493:Folic Acid Antagonists / Q000494:pharmacology*; D006801:Humans; D007938:Leukemia / Q000378:metabolism / Q000473:pathology; D011739:Pyrimethamine / Q000031:analogs & derivatives / Q000494:pharmacology; D011799:Quinazolines / Q000494:pharmacology*; D013938:Thymidine Monophosphate / Q000096:biosynthesis*; D013940:Thymidylate Synthase / Q000032:analysis / Q000037:antagonists & inhibitors; D013942:Thymine Nucleotides / Q000032:analysis / Q000096:biosynthesis*
D003848:Deoxyguanine Nucleotides; D005493:Folic Acid Antagonists; D011799:Quinazolines; D013942:Thymine Nucleotides; D005467:Floxuridine; C006308:metoprine; D013938:Thymidine Monophosphate; C035530:5,8-dideazaisofolic acid; C029603:deoxyguanosine triphosphate; D004247:DNA; D013940:Thymidylate Synthase; D004257:DNA Polymerase II; C024157:thymidine 5'-triphosphate; D011739:Pyrimethamine